Pharmacokinetics of nadolol in children with supraventricular tachycardia.
The pharmacokinetics of intravenous and oral nadolol, a long-acting beta-adrenoceptor blocking agent, were investigated in six children receiving the drug for treatment of supraventricular tachycardia. In the youngest patient (age 3 months), no distribution phase was seen. In children younger than 22 months of age, nadolol is more rapidly eliminated (t1/2 = 4.3 hours or less) than in older children, in whom elimination is more similar to that in adults (t1/2 approximately 7.3-15.7 hours). After intravenous administration, nadolol displayed two-compartment pharmacokinetics with a distribution phase (t1/2 = 0.2-1.1 hours) followed by elimination. Large changes in nadolol pharmacokinetics may occur during the first year of life. Nadolol should be used cautiously in infants.
Mehta
A V
AV
Department of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City 37614-0578.
Chidambaram
B
B
Rice
P J
PJ
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D009248:Nadolol / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013617:Tachycardia, Supraventricular / Q000188:drug therapy / Q000378:metabolism*
D009248:Nadolol